Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: The MONOI-ANRS136 Substudy

HIV Medicine

Volumn 13, Issue 8, 2012, Pages 505-515

  Valantin, M A ^a,b   Kolta, S ^c   Flandre, P ^a,b   Algarte Genin, M ^a   Meynard, J L ^d   Ponscarme, D ^e   Slama, L ^f   Cuzin, L ^g   de Kerviler, E ^e   Inaoui, R ^b   Katlama, C ^a,b  

^a INSERM   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f HÔPITAL TENON   (France)

^g CHU PURPAN   (France)

Author keywords

Darunavir; HIV lipodystrophy; MONOI; Protease inhibitor monotherapy

Indexed keywords

ABACAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; BODY FAT; BODY FAT DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRUNK;

ADULT; BODY FAT DISTRIBUTION; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SULFONAMIDES;

EID: 84864299353     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2012.01004.x     Document Type: Article

References (38)

1. Guaraldi G, Baraboutis IG. Evolving perspectives on HIV-associated lipodystrophy syndrome: moving from lipodystrophy to non-infectious HIV co-morbidities. J Antimicrob Chemother 2009; 64: 437-440.
2. Glass TR, Battegay M, Cavassini M etal. Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2010; 54: 197-203.
3. Martin A, Smith DE, Carr A etal. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18: 1029-1036.
4. McComsey GA, Ward DJ, Hessenthaler SM etal. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004; 38: 263-270.
5. Moyle GJ, Sabin CA, Cartledge J etal. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20: 2043-2050.
6. Tebas P, Zhang J, Hafner R etal. Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110. J Antimicrob Chemother 2009; 63: 998-1005.
7. Valantin MA, Lanoy E, Bentata M etal. Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial. HIV Med 2008; 9: 625-635.
8. Negredo E, Miro O, Rodriguez-Santiago B etal. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). Clin Infect Dis 2009; 49: 892-900.
9. Horberg M, Tang B, Towner W etal. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr 2010; 53: 62-69.
10. Sabin CA, Worm SW, Weber R etal. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371: 1417-1426.
11. Cameron DW, da Silva BA, Arribas JR etal. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis 2008; 198: 234-240.
12. Campo RE, Lalanne R, Tanner TJ etal. Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients. AIDS 2005; 19: 447-449.
13. Pulido F, Perez-Valero I, Delgado R etal. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antivir Ther 2009; 14: 195-201.
14. Ortiz R, Dejesus E, Khanlou H etal. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22: 1389-1397.
15. Arribas JR, Horban A, Gerstoft J etal. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010; 24: 223-230.
16. Katlama C, Valantin MA, Algarte-Genin M etal. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010; 24: 2365-2374.
17. De Meyer S, Lathouwers E, Dierynck I etal. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. AIDS 2009; 23: 1829-1840.
18. Madruga JV, Berger D, McMurchie M etal. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370: 49-58.
19. Mills AM, Nelson M, Jayaweera D etal. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009; 23: 1679-1688.
20. Katlama C, Esposito R, Gatell JM etal. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21: 395-402.
21. Yilmaz A, Izadkhashti A, Price RW etal. Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res Hum Retroviruses 2009; 25: 457-461.
22. Boffito M, Miralles D, Hill A. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100mg once-daily in treatment-naive and -experienced patients. HIV Clin Trials 2008; 9: 418-427.
23. Blake GM, Fogelman I. An update on dual-energy x-ray absorptiometry. Semin Nucl Med 2010; 40: 62-73.
24. Graat-Verboom L, Spruit MA, van den Borne BE etal. Whole-Body versus Local DXA-Scan for the Diagnosis of Osteoporosis in COPD Patients. J Osteoporos 2010; 2010: 640878.
25. Baumgartner RN, Koehler KM, Gallagher D etal. Epidemiology of Sarcopenia among the Elderly in New Mexico. Am J Epidemiol 1998; 147: 755-763.
26. Kanis JA, WHO study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO Report. Osteoporos Int 1994; 4: 368-381.
27. Stevens J, Katz EG, Huxley RR. Associations between gender, age and waist circumference. Eur J Clin Nutr 2010; 64: 6-15.
28. McComsey GA, Kitch D, Sax PE etal. Peripheral and Central Fat Changes in Subjects Randomized to Abacavir-Lamivudine or Tenofovir-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: ACTG Study A5224s. Clin Infect Dis 2011; 53: 185-196.
29. Carr A, Samaras K, Thorisdottir A etal. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-2099.
30. Ferrer E, Del Rio L, Martinez E etal. Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults. AIDS Res Hum Retroviruses 2011; 27: 1061-1065.
31. Haubrich RH, Riddler SA, DiRienzo AG etal. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009; 23: 1109-1118.
32. Berker D, Koparal S, Isik S etal. Compatibility of different methods for the measurement of visceral fat in different body mass index strata. Diagn Interv Radiol 2010; 16: 99-105.
33. De Wit S, Sabin CA, Weber R etal. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008; 31: 1224-1229.
34. Bonjoch A, Figueras M, Estany C etal. Osteoporosis Study Group. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 2010; 24: 2827-2833.
35. Cazanave C, Dupon M, Lavignolle-Aurillac V etal. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008; 22: 395-402.
36. Mary-Krause M, Ename-Mkoumazok B, Bentata M etal. Prevalence of low bone mineral density in HIV-1 infected men and women and proposal for a screening strategy. 12th European Aids Conference (EACS). Cologne, Germany, November 2009 [Abstract n° PS5/3].
37. McComsey GA, Kitch D, Daar ES etal. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202. J Infect Dis 2011; 203: 1791-1801.
38. Stellbrink HJ, Orkin C, Arribas JR etal. ASSERT Study Group. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51: 963-972.